16th Annual World ADC London 2026

Piet van der Graaf, PharmD, PhD, Senior Vice President and Head of Quantitative Systems Pharmacology, will participate in a panel discussion on how Model-Informed Drug Development (MIDD) accelerates ADC discovery and development. The session will highlight Certara’s ADC EFA platform, showcase real-world case studies, and reference research from Eline van Maanen, Director, on pharmacometric approaches for ADCs.

Presenter: Eline van Maanen

Authors: Thijs Zweers (1), Eline van Maanen (1), Sinziana Cristea (1), Stephen Duffull (1), Anne Chain (2), Carolina de Miranda Silva (2), Cindy Zhang (2), Azher Hussain (2), Yezhe Cheng (3)

Institution:(1) Certara, Radnor, PA, USA (2) Merck & Co., Inc., Rahway, New Jersey, USA (3) Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, China.

Sacituzumab tirumotecan, a TROP2-targeting ADC, was characterized using a semi-mechanistic population PK (popPK) model, leveraging total ADC, total mAb and payload data from 2 phase I/II clinical trials (NCT04152499, NCT05631262). The model simultaneously described the concentration data of total ADC, total mAb and payload incorporating DAR species and payload release mechanisms through hydrolytic degradation of ADC and due to DAR species conversion. This approach enables comprehensive characterization of PK and supports dose optimization to minimize adverse events in clinical development.